The 12‐year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia

• Published in: BJU international 2004-12, Vol.94 (9), p.1271-1274
• Main Authors: Masood, Shikohe, Djaladat, Hooman, Kouriefs, Chryssanthos, Keen, Margaret, Palmer, John H.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Analysis of Variance; benign prostatic hyperplasia; Biological and medical sciences; Follow-Up Studies; Genital system. Mammary gland; Humans; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; outcome; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - surgery; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Statistics, Nonparametric; Stents; Treatment Outcome; Tumors of the urinary system; Urinary Incontinence - etiology; Urinary Incontinence - surgery; urinary retention; Urinary Retention - etiology; Urinary Retention - surgery; Urinary tract. Prostate gland; UrolumeTM wallstent
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/j.1464-410X.2004.05155.x

OBJECTIVE To evaluate the long‐term results of using the UrolumeTM endourethral prosthesis (American Medical Systems, Minnetonka, MN, USA) for managing benign prostatic hyperplasia (BPH), an alternative minimally invasive option. PATIENTS AND METHODS Sixty‐two patients with moderate/severe lower urinary tract symptoms secondary to BPH were treated with the Urolume stent by one surgeon (J.H.P.). They were followed up at 12 weeks, 6 months and then yearly. Data recorded before and after treatment included symptom scoring, peak urinary flow rate (PFR) and postvoid residual volume (PVR). A one‐way anova was used to compare baseline and the 5‐ and 12‐year follow‐up data. RESULT Twenty‐two and 11 patients completed the 5‐ and 12‐year follow‐up, respectively. Twenty‐one (34%) patients died with the stent in situ from causes unrelated to BPH and Urolume insertion. Twenty‐nine (47%) stents were removed; 18 in the first 2 years, seven at 3–5 years and four at 9–10 years. Early stent explantation was primarily a result of poor case selection, or stent malposition/migration. Four stents were removed because the patient was dissatisfied. Late stent explantation was for symptom progression. At 5 years, the symptom score and PFR were 6.82 an 11.7 mL/s, respectively, compared with 20.4 and 9 mL/s at basleine (P